Iovance Biotherapeutics, Inc. (IOVA)
NASDAQ: IOVA · IEX Real-Time Price · USD
13.63
+0.75 (5.82%)
At close: May 3, 2024, 4:00 PM
13.69
+0.06 (0.44%)
After-hours: May 3, 2024, 7:55 PM EDT
Iovance Biotherapeutics Employees
Iovance Biotherapeutics had 557 employees on December 31, 2023. The number of employees increased by 54 or 10.74% compared to the previous year.
Employees
557
Change (1Y)
54
Growth (1Y)
10.74%
Revenue / Employee
$2,135
Profits / Employee
-$797,194
Market Cap
3.81B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 557 | 54 | 10.74% |
Dec 31, 2022 | 503 | 184 | 57.68% |
Dec 31, 2021 | 319 | 78 | 32.37% |
Dec 31, 2020 | 241 | 93 | 62.84% |
Dec 31, 2019 | 148 | 60 | 68.18% |
Dec 31, 2018 | 88 | 25 | 39.68% |
Dec 31, 2017 | 63 | 12 | 23.53% |
Dec 31, 2016 | 51 | 31 | 155.00% |
Dec 31, 2015 | 20 | 6 | 42.86% |
Dec 31, 2014 | 14 | 9 | 180.00% |
Dec 31, 2013 | 5 | 3 | 150.00% |
Dec 31, 2012 | 2 | 0 | - |
Dec 31, 2011 | 2 | -3 | -60.00% |
Dec 31, 2010 | 5 | 1 | 25.00% |
Dec 31, 2009 | 4 | 2 | 100.00% |
Dec 31, 2008 | 2 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Envista Holdings | 12,800 |
LivaNova | 2,900 |
Oscar Health | 2,400 |
iRhythm Technologies | 2,000 |
Ultragenyx Pharmaceutical | 1,276 |
Axonics | 797 |
Prestige Consumer Healthcare | 560 |
Axsome Therapeutics | 545 |
IOVA News
- 2 days ago - Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024 - GlobeNewsWire
- 3 days ago - Iovance Biotherapeutics to Present at Upcoming Conferences - GlobeNewsWire
- 9 days ago - Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting - GlobeNewsWire
- 14 days ago - Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics Announces FDA has Lifted Clinical Hold on the IOV-LUN-202 Registrational Trial in Non-Small Cell Lung Cancer - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Wednesday, February 28, 2024 - GlobeNewsWire
- 2 months ago - Iovance Biotherapeutics Stock Rockets 41% Higher. Here's Why. - Barrons